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Component resolution reveals additional major allergens in
patients with honeybee venom allergy
Julian K€ohler, MS,a* Simon Blank, PhD,b* Sabine M€uller, MD,a Frank Bantleon, DiplBiol,b Marcel Frick, MS,a
Johannes Huss-Marp, MD,a,c Jonas Lidholm, PhD,d Edzard Spillner, PhD,b and Thilo Jakob, MDa Freiburg and
Hamburg, Germany, and Uppsala, SwedenBackground: Detection of IgE to recombinant Hymenoptera
venom allergens has been suggested to improve the diagnostic
precision in Hymenoptera venom allergy. However, the
frequency of sensitization to the only available recombinant
honeybee venom (HBV) allergen, rApi m 1, in patients with
HBVallergy is limited, suggesting that additional HBVallergens
might be of relevance.
Objective: We performed an analysis of sensitization profiles of
patients with HBVallergy to a panel of HBV allergens.
Methods: Diagnosis of HBV allergy (n 5 144) was based on
history, skin test results, and allergen-specific IgE levels to HBV.
IgE reactivity to 6 HBV allergens devoid of cross-reactive
carbohydrate determinants (CCD) was analyzed by
ImmunoCAP.
Results: IgE reactivity to rApi m 1, rApi m 2, rApi m 3, nApi m 4,
rApi m 5, and rApi m 10 was detected in 72.2%, 47.9%, 50.0%,
22.9%, 58.3%, and 61.8% of the patients with HBV allergy,
respectively. Positive results to at least 1 HBV allergen were
detected in 94.4%. IgE reactivity to Api m 3, Api m 10, or both
was detected in 68.0% and represented the only HBV allergen–
specific IgE in 5% of the patients. Limited inhibition of IgE
binding by therapeutic HBV and limited induction of Api m
3– and Api m 10–specific IgG4 in patients obtaining
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Open access under CC BY-NC-SA license.underrepresentation of these allergens in therapeutic HBV
preparations.
Conclusion: Analysis of a panel of CCD-free HBV allergens
improved diagnostic sensitivity compared with use of rApi m
1 alone, identified additional major allergens, and revealed
sensitizations to allergens that have been reported to be absent
or underrepresented in therapeutic HBV preparations.
(J Allergy Clin Immunol 2014;133:1383-9.)
Key words: Apis mellifera, cross-reactive carbohydrate determi-
nant, Hymenoptera venom, insect venom allergy, honeybee venom
allergy, recombinant allergen, Vespula vulgaris
Diagnosis of Hymenoptera venom allergy is commonly based
on a history of anaphylactic sting reactions, positive skin test
results, and/or detection of specific IgE to venom of honeybee or
Vespula species.1 Positive results on skin and serologic tests
with conventional venom preparations are frequently caused by
antibodies cross-reactive to conserved structures found in venom
allergens. These include homologous primary structures of
protein allergens (eg, hyaluronidases, dipeptidyl peptidases IV,
and vitellogenins) and cross-reactive carbohydrate determinants
(CCD),2,3 which are present on the majority of Hymenoptera
venom allergens.4 Double positivity to honeybee venom (HBV)
and yellow jacket venom (YJV) in patients who have not
been able to identify the culprit insect necessitates additional
laboratory tests (eg, IgE inhibition assays or basophil activation
tests)5,6 that are expensive, time-consuming, difficult to interpret,
and therefore rarely used in the clinical routine.
Recently, the diagnostic value of IgE detection to CCD-free,
species-specific recombinant Hymenoptera venom allergens,
such as HBV phospholipase A2 (rApi m 1), YJV phospholipase
A1 (rVes v 1), and antigen 5 (rVes v 5), was demonstrated.
7-14
In contrast to the situation of YJV allergy,7,9,14,15 the frequency
of sensitization to rApi m 1, the only recombinant HBVallergen
commercially available to date, in patients with HBV allergy
ranges from 58% to 80%,7,8,10,13,14,16 which is insufficient to
support a definitive diagnosis of HBV allergy. This suggests that
additional HBV allergens are of relevance for sensitization and
hence the diagnosis of HBV allergy.
The best characterized HBV allergens are phospholipase A2
(Api m 1), hyaluronidase (Api m 2), and the basic peptide melittin
(Api m 4), which all constitute medium- to high-abundance
proteins.17,18 More recently, additional HBV allergens of lower
abundance have been cloned and characterized, such as acid
phosphatase (Api m 3),19 dipeptidylpeptidase IV (Api m 5),20
Api m 6,21 major royal jelly proteins 8 and 9 (Api m 11.0101
and Api m 11.0201),22 icarapin (Api m 10),23,24 and vitellogenin
(Api m 12).25 Insect cell–based expression strategies allowed for
detection of IgE reactivity of these allergens independent of1383
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analysis of different venom preparations, demonstrating that
lower-abundance components, such as Api m 3 and Api m 10,
although present in the crude HBV, are absent or underrepre-
sented in preparations used for HBV immunotherapy.23
Herewe analyzed the sensitization profile of patients with HBV
allergy to a panel of CCD-free HBVallergens, including rApim 1,
rApi m 2, rApi m 3, nApi m 4, rApi m 5, and rApi m 10, by using
the ImmunoCAP assay system (Thermo Fisher Scientific,
Uppsala, Sweden). Inclusion of additional allergens improved
the sensitivity of component-based diagnostics and demonstrated
distinct sensitization profiles, some of which displayed prominent
sensitizations to Api m 3 and Api m 10. In the same line,
we observed a lack of Api m 3– and Api m 10–specific
IgG4 induction during HBV immunotherapy, suggesting that
sensitization profiles to allergens that are not sufficiently present
in therapeutic HBV preparations might be of relevance for the
outcome of HBV immunotherapy.METHODS
Patients
Sera from 184 patients with anaphylactic reactions to either honeybee
(n5 144) or yellow jacket (n5 40) stings (as identified by the patient) and 40
HBV-nonallergic control subjects were analyzed. Diagnosis of HBV allergy
was based on a combination of the patient’s history of an anaphylactic
sting reaction, a positive skin test result, and positive IgE levels to HBV
(ImmunoCAP i1), as recently described.14 As defined by the inclusion criteria,
all patients with HBV allergy displayed IgE to HBV (>_0.35 kUA/L), and 90
(62.5%) also had positive test results to YJV (ImmunoCAP i3). Diagnosis
of YJV allergy was based on a combination of the patient’s history of yellow
jacket sting anaphylaxis, a positive skin test result, and positive IgE results for
YJV (ImmunoCAP i3) and negative results for HBV (ImmunoCAP i1). The
HBV-nonallergic control subjects had all experienced a bee sting, although
without an anaphylactic or large local reaction. All patients and control
subjects had provided informed written consent, and the study was approved
by the local ethics committee.Allergens and IgE antibody measurements
rApi m 2, rApi m 3, rApi m 5, and rApi m 10 were expressed as secreted
full-length proteins by Spodoptera frugiperda (Sf9) insect cells, as recently
described.12,19,20,23,26,27 In brief, Sf9 cells were grown in suspension at 278C
in serum-free medium (Lonza, Verviers, Belgium) containing 10 mg/mL
gentamicin (Invitrogen, Carlsbad, Calif) to a density of 1.5 3 106 cells per
milliliter and then infected with a high-titer stock of recombinant baculovirus
containing the allergen gene to be expressed. For protein production, the cells
were incubated at 278C and 110 rpm for 72 hours. The recombinant proteins
were then purified from culture medium by using a nickel-chelating affinity
matrix (NTA-agarose; Qiagen, Hilden, Germany). The purity of each
recombinant protein was assessed by using SDS-PAGE (see Fig E1 in this
article’s Online Repository at www.jacionline.org).
Api m 4 was purified from HBV by means of sequential steps of
ion exchange and size exclusion chromatography. The purity of thepreparation was assessed immunologically and by using SDS-PAGE
(not shown).
Experimental ImmunoCAP tests (Thermo Fisher Scientific) containing
the purified HBV allergens were prepared, as previously described.28
All IgE antibody measurements were performed with a Phadia 250 instru-
ment, according to the manufacturer’s instructions (Thermo Fischer
Scientific).Immunoreactivity of patient sera
Serum IgE reactivity was analyzed on a CAP-FEIA platform (Phadia
250) using commercially available ImmunoCAP tests for HBV (Immuno-
CAP i1), YJV (ImmunoCAP i3), rApi m 1 (ImmunoCAP i208), rVes v 5
(ImmunoCAP i209), rVes v 1 (ImmunoCAP i211), and the CCD marker
MUXF3 (ImmunoCAP i213) and experimental ImmunoCAP tests for rApi
m 2, rApi m 3, nApi m 4, rApi m 5, and rApi m 10. Selected sera were also
analyzed for IgE reactivity to major royal jelly protein 8 and 9 (Api m
11.0101 and Api m 11.0201) and 3 additional HBV proteins (not been
assigned as allergens) by using ELISA, as recently described.22 Allergen-
specific IgG4 reactivity to rApi m 1, nApi m 4, rApi m 3, and rApi m 10
in selected sera was analyzed by using a Phadia 250 instrument and 1:100
or 1:20 serum dilutions.CAP-FEIA inhibition
Inhibition of allergen-specific IgE (sIgE) binding toHBV (ImmunoCAP i1)
by nApi m 1 (Latoxan, Valence, France), rApi m 3, or rApi m 10 was
performed by means of preincubation of patient sera and inhibitors at the
indicated concentrations for 2 hours at room temperature before the
CAP-FEIA analysis. Alternatively, sera were preincubated with a crude
HBV preparation (Latoxan) or solubilized freeze-dried therapeutic HBV
preparations (ie, not absorbed to alum) at 300 mg/mL.RESULTS
IgE reactivity to HBV allergens in patients with
HBV allergy, patients with YJV allergy, and
HBV-nonallergic control subjects
IgE reactivity (>_0.35 kUA/L) to the commercially available
rApi m 1 (i208) was detected in 72.2%, to rApi m 2 in 47.9%,
to rApi m 3 in 50.0%, to nApi m 4 in 22.9%, to rApi m 5 in
58.3%, and to rApi m 10 in 61.8% of patients with HBV allergy
(Fig 1). In patients with YJV allergy, no relevant IgE reactivity
was detected, except to rApi m 5 (3/40, Fig 1), the cross-
reactive dipeptidylpeptidase also present in YJV as Ves v 3. Of
the 40 HBV-nonallergic control subjects, 6 (15%) displayed IgE
reactivity of 0.35 kUA/L or greater to HBV (ImmunoCAP i1),
which is in line with previous reports.29 In this subgroup of 6 con-
trol subjects, IgE reactivity to rApi m 1 was detected in 3, to rApi
m 5 in 2, and to rApi m 10 in 1 subjects. No IgE reactivity to any of
the tested HBV allergens was detected in the ImmunoCAP i1
negative control sera (Fig 1). Among the patients with HBV
allergy, positive results to at least 1 HBV allergen were detected
in 94.4%, and positive results to at least 1 of the HBV-specific
allergens Api m 1, 3, 4, or 10 were detected in 89.6% (Fig 2).
The majority of patients with HBV allergy were sensitized to
more than 1 allergen (74.3%), and a minority (9.7%) were sensi-
tized to all allergens tested. Interestingly, HBV-monosensitized
patients (n 5 54) had lower total IgE levels, lower levels of
sIgE to HBV (ImmunoCAP i1), and lower levels of sIgE to all
HBVallergens tested when compared with patients with HBVal-
lergy who were also sensitized to YJV (ImmunoCAP i3, n5 90;
see Table E1 in this article’s Online Repository at www.
jacionline.org).
FIG 1. IgE immunoreactivity of individual patient sera with recombinant allergens. IgE reactivity to HBV
allergens of sera from patients with HBV allergy (n 5 144), patients with YJV allergy (n 5 40), and
HBV-exposed but nonallergic control subjects (NA; n 5 40). The lower-end cutoff of the CAP-FEIA
(<0.35 kUA/L) is represented as a dotted line.
FIG 2. Diagnostic sensitivity of sIgE to different combinations of HBV
allergens. Detection of IgE reactivity to a panel of HBV allergens increases
diagnostic sensitivity in patients with HBV allergy (n 5 144).
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Among the patients with HBV allergy, 39 of 64 possible
different sensitization profiles were present, and the 10 most
frequent profiles covered 64% of the study population (see Table
E3 in this article’s Online Repository at www.jacionline.org). As
suggested from analysis of IgE profile complexity,30 the number
of allergens detected showed a clear association with the
concentration of sIgE to HBV. Interestingly, the HBVmonosensi-
tized patients mostly display lower sIgE levels to lower numbers
of allergens (cluster on the left side), while the HBV and YJV
double-sensitized patients recognize multiple bee venom
allergens (cluster on the right; see Fig E2 in this article’s Online
Repository at www.jacionline.org). IgE reactivity to Api m 3,
Api m 10, or both was detected in 68% of the patients, and 7
(4.8%) patients displayed IgE reactivity exclusively to Api m 3,
Api m 10, or both. This is of particular interest because Api m
3 and Api m 10 have been demonstrated to be absent or underrep-
resented in HBV preparations used for immunotherapy.19,23IgE reactivity to HBV allergens in relation to whole
HBV
IgE reactivity to HBV (ImmunoCAP i1) displayed a significant
correlation (r5 0.94, P <.0001) with the sum of IgE reactivity to
Apim 1, Apim 2, Api m 3, Api m 4, Apim 5, Api m 10, andCCDs(Fig 3, A). The relative contribution of sIgE to the different
allergens was calculated in relation to and expressed as a
percentage of sIgE to HBV (ImmunoCAP i1; Fig 3, B and C).
The relative IgE reactivity to Api m 3 (median, 7%; 25% to
75% interquartile range [IQR25/75], 3%/14%) and Api m 10
(median, 14%; IQR25/75, 5%/28%), even though lower than
the relative IgE reactivity to Api m 1 (median, 20%; IQR25/75,
9%/49%), suggests a relevant role in HBV allergy.
CAP-FEIA inhibition experiments with titrated doses of
recombinant allergens in equimolar concentrations (Fig 4, A) in
patients either sensitized to Api m 1 and not to Api m 10 (Api
m 11 Api m 102) or vice versa (Api m 12 Api m 101) confirmed
the relative contribution of IgE directed against Api m 1 and Api
m 10. Similarly, the degree of maximal inhibition with Api m 1,
Api m 3, and Api m 10 correlated with the calculated relative
IgE reactivity (Fig 4, B). Inhibition of HBV sIgE reactivity by
different HBV preparations, such as crude HBV or therapeutic
preparations, provided a means to demonstrate the presence of
individual allergens in the preparation. For the predominantly
Api m 1–positive sera, both a crude and a therapeutic HBV
preparation blocked the IgE binding to a similar degree. In
contrast, in predominantly Api m 10–positive sera (relative
IgE reactivity, 54%; range, 35% to 72%), therapeutic HBV
preparations were clearly less effective compared with a crude
HBV preparation (Fig 4, C). This result is consistent with the
previously reported absence of Api m 10 from therapeutic HBV
preparations.23HBV allergen–specific IgG4 during HBV
immunotherapy
Finally, we analyzed IgG4 responses to the HBV-specific
allergens Api m 1, Api m 3, Api m 4, and Api m 10 in 20 patients
who had undergone HBV immunotherapy for 12 to 48 months.
A prominent induction of sIgG4 was observed for the 2 highly
abundant allergens Api m 1 and Api m 4, which was comparable
with that observed with whole HBV. In contrast, no or very little
sIgG4 induction was observed for the low-abundance allergens
FIG 3. IgE reactivity to single HBV allergens in relation to sIgE to HBV.A, IgE
reactivity to HBV (ImmunoCAP i1) in patients with HBV allergy (n 5 144) in
relation to the sum of IgE reactivity to Apim 1, Apim 2, Apim 3, Apim 4, Api
m 5, Api m 10, and CCDs. B, The relative sIgE reactivity to single HBV
allergens was calculated as a ratio of sIgE reactivity to HBV and displayed
as a whisker plot with medians; 5th, 25th, 75th, and 95th percentiles; and
outliers. C, The median was used to present the relative contribution to
IgE reactivity of single allergens as a pie chart.
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m 3 and Api m 10 might be underrepresented in therapeutic HBV
preparations.DISCUSSION
In this study we addressed the component resolution of
IgE sensitization in a large set of sera from patients with HBV
allergy to a broad panel of different recombinant high- and
low-abundance HBV allergens. Component resolution at thislevel in clinical diagnosis of HBV allergy is not yet possible
because of the commercial unavailability of most of the HBV
allergens required. Recently, we and others have extended the
small set of allergens in the databases, including Api m 1, Api m
2, and Api m 4, to a broad panel of allergens up to Api m 12.25
For the production of complex and often high-molecular-
weight Hymenoptera venom allergens, insect cells recently
turned out to be an appropriate system in terms of functionality,
epitope authenticity, glycosylation, and folding.12,20,31 IgE with
specificity for CCDs plays a key role in allergen cross-reactivity
and represents a major concern for the specificity of diagnostic
approaches in patients with Hymenoptera venom allergy.2,4,5,12
We recently demonstrated that the use of Sf9 insect cells for
allergen expression represents a strategy to circumvent the
establishment of CCDs while maintaining the advantages of a
nearly autologous expression system.12,22,23,26 A recent study
also suggested that the IgE reactivity of rApi m 1 compared
with the native protein is not affected by the presence of a
his-tag.16 In addition, using his-tagged recombinant maltose
binding protein, we did not observe any his-tag–based IgE
reactivity in patients with HBV allergy (data not shown).
Almost all patients with HBV allergy in this study (136/144)
proved to have specific IgE antibodies against at least 1 of the
HBV allergens included in our panel. Api m 1 remains the
most frequently recognized allergen, and its introduction in
recombinant and CCD-free forms has been helpful toward
improved clinical diagnosis and a better understanding of the
molecular sensitization pattern in HBVallergy.7,16 Although it is
clearly justified to regard Api m 1, through frequent sensitization
and high abundance in HBV, as the single most important
determinant of HBV allergenicity, the results presented here
demonstrate that sensitization to HBV is considerably more
complex than previously recognized.
In the present study nearly half of the patients with HBVallergy
displayed IgE reactivity against the HBV hyaluronidase Api m 2,
supporting the previously reported role of Api m 2 as the relevant
HBVallergen.12,14 Double positivity to HBVand YJV, apart from
CCDs, in patients with venom allergy has previously been largely
attributed to IgE directed against either hyaluronidases (Api m 2
and Ves v 2)32 or dipeptidylpeptidases (Api m 5 and Ves v 3).20
However, recent studies have indicated that cross-reactivity
between hyaluronidases is limited.12,33,34 The acid phosphatase
Api m 3 is a classical and species-specific allergen without
homologues in YJV that has been cloned recently.19 IgE reactivity
to rApi m 3 in 50% of the patients with HBVallergy corroborates
its relevance as a major HBV allergen.
The peptidic HBVallergen Api m 4 is the only nonrecombinant
component used in this study. Even though it represents the bulk
of the venom dry weight and 2 patients showed detectable IgE
exclusively to Api m 4 (0.54 and 0.40 kUA/L), the moderate
frequency of sensitization and its low overall contribution to
IgE binding towhole HBV suggests a limited clinical importance.
IgE reactivity to the dipeptidyl peptidase IVallergen Api m 5 in
58% and to Api m 10 in 62% of the patient population establishes
both as major allergens in HBVallergy. Similar to Api m 1, Api m
3, and Api m 4, Api m 10 is a species-specific allergen and hence
constitutes an important molecule for diagnostic and therapeutic
considerations.
It is evident from our data that Api m 1, Api m 3, Api m 5, and
Api m 10 are major HBV allergens. This number is higher than
anticipated, and inclusion of additional major allergens into
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diagnosis. In our opinion the best approach to apply these new
components would be to add them to the repertoire of availableallergens, either as single components or as selected combinations
of recombinant allergens that allow species-specific diagnosis of
HBV allergy in those patients who display HBV and YJV
double-positive results and thus cannot receive clear diagnosis
by using extract-based tests.
Among the patients with HBV allergy who displayed sIgE
to HBV (ImmunoCAP i1) but had negative results for Api m 1
(n 5 40), IgE reactivity was detected in 47.5% to Api m 2, in
27.5% to Api m 3, in 17.5% to Api m 4, in 40% to Api m 5, and in
52.5% to Api m 10. Sensitization to only 1 allergen was observed
in 29 patients (Api m 1, n5 17; Api m 2, n5 3; Api m 4, n5 2;
Api m 5, n5 1; and Api m 10, n5 6). Thus all allergens included
here demonstrated a potential additional value in the molecular
diagnostics of HBVallergy. In contrast, sera from patients with a
convincing history of anaphylactic bee sting reactions that were
negative for sIgE to HBV (ImmunoCAP i1, n5 14) and thus not
included in our study population were also negative for sIgE to all
of the HBV-specific components tested (see Table E4 in this
article’s Online Repository at www.jacionline.org).
Because vespid homologues exist for both Api m 2 and Api m
5, we expected some of the IgE reactivity to these allergens to be
related to a concomitant sensitization to YJV, which is in contrast
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m 10. Interestingly, in patients with HBV allergy, concomitant
sensitization to YJV was associated with a higher level of total
IgE and HBV sIgE (ImmunoCAP i1), as well as higher levels of
sIgE to all HBVallergens tested (see Table E1), suggesting effects
that were independent of cross-reactivity at the protein level. We
observed the same phenomenon (higher total and sIgE levels in
double-sensitized compared with monosensitized patients) in a
separate population of patients with YJV allergy (n 5 170, see
Table E2 in this article’s Online Repository at www.jacionline.
org),15 suggesting that this might reflect a more advanced state
of atopic immune deviation in the double-sensitized population
compared with the monosensitized population. This is in part
supported by the observation that HBV-monosensitized
patients mostly display lower sIgE levels to lower numbers of
allergens, whereas double-sensitized patients recognize multiple
bee venom allergens (see Fig E2 in this article’s Online
Repository at www.jacionline.org). Similar findings have
recently also been reported for sensitization to Phleum pratense
allergens.35
A few sera of patients with HBVallergy who displayed sIgE to
HBV (ImmunoCAP i1) were found to be negative for all
HBV-specific allergens. These sera were additionally tested by
using additional HBV proteins, including Api m 11.0101 and Api
m 11.020122 and 3 novel components (a venom protease, C1q,
and PVF-1, which have not been designated as allergens thus
far; data not shown). Thereby a further 3 sera were found to be
positive: 1 for the venom protease, 1 for Api m 11.0201 and
C1q, and 1 for C1q. These results clearly suggest that increasing
the numbers of components certainly can increase the sensitivity
of component-resolved diagnostics to a level at which virtually all
patients with HBVallergy can be detected. These data also show
that the individual sensitization profiles of patients with HBV
allergy are more complex than anticipated. The level of
complexity of patients’ sensitization patterns clearly correlates
with HBV-specific IgE levels, a finding that is similar to those
reported from component-resolved studies in pollen-sensitized
patients.30,36 Notably, 39 of 64 possible different sensitization
profiles were present, and the 10 most frequent profiles covered
64% of our study population (see Table E3). In an attempt to
estimate the contribution of Api m 10 compared with Api m 1,
we calculated the relative IgE reactivity in relation to IgE to
HBV (ImmunoCAP i1). In the entire population with HBV
allergy, IgE reactivity to rApi m 10 was on the order of two
thirds of that to rApi m 1. Because this approach allows an
approximation only, we performed CAP inhibition with Api m
1, Api m 3, or Api m 10 in patients who showed a predominant
sensitization to either of the allergens. The degree of maximal
inhibition with Api m 1, Api m 3, and Api m 10 correlated well
with the calculated relative IgE reactivity, suggesting that at least
for these 3 allergens, this parameter can be used to estimate the
magnitude of IgE binding of the respective allergen.
In light of the prominent IgE reactivity to Api m 10 and the
recent report of absence or underrepresentation of low-abundance
allergens, such as Api m 10 and Api m 3, in therapeutic HBV
preparations, we analyzed the efficacy of different HBV
preparations to block IgE binding to HBV (ImmunoCAP i1) in
patients who were predominantly sensitized to Api m 10. Our
inhibition studies clearly suggested that Api m 10 is underrepre-
sented in the therapeutic HBV preparations when compared with
the crude HBV. If a patient’s IgE reactivity to HBV (ImmunoCAPi1) predominantly comprises IgE to Api m 10, the use of
therapeutic HBV preparations apparently lacking Api m 10might
not lead to the desired therapeutic tolerance induction. With the
tools of component-resolved diagnostics at our hands, we might
be able to address this issue.
As a first step in this direction, we simply addressed the
question of whether HBV immunotherapy leads to specific IgG4
induction to the respective HBV allergens. In contrast to the
prominent induction of sIgG4 against the 2 high-abundance
allergens Api m 1 and Api m 4, no or very little induction of
sIgG4 to Api 3 and Api m 10 was observed. This observation is
consistent with previous reports that Api m 3 and Api m 10 are
underrepresented in therapeutic HBV preparations.9,23
In summary, the analysis of IgE reactivity to a large panel of
CCD-free bee venom allergens improves the sensitivity and
precision of component-based diagnostics in patients with HBV
allergy. In addition, the component resolution allowed the
identification of distinct sensitization profiles. Prominent IgE
reactivity to some allergens that are absent or underrepresented in
therapeutic HBV preparations suggests that different profiles
might be of relevance for the success of HBV immunotherapy.
Future studies will need to address these issues, in particular
whether distinct HBV sensitization profiles can be used as
predictors for the outcome of HBV immunotherapy.
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Clinical implications: Patients with bee venom allergy display
distinct sensitization profiles to a panel of HBV allergens,
some of which have been reported to be absent or underrepre-
sented in therapeutic HBV preparations.
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FIG E1. Recombinant expression and immunoreactivity of venom
allergens. SDS-PAGE analyses of the purified recombinant allergens
Api m 1, Api m 2, Api m 3, Api m 5, and Api m 10, as visualized by using
Coomassie blue staining.
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FIG E2. Relationship between levels of sIgE to HBV and the number of
different HBV allergens recognized in HBV-monosensitized (A) and HBV
and YJV double-sensitized patients (B).
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TABLE E1. Total IgE, sIgE to BV extract and to CCD-free HBV allergens Api m 1, Api m 2, Api m 3, Api m 4, Api m 5 and Api m 10 in
HBV-allergic patients monosensitized to HBV extract or double sensitized to HBV and YJV extract
Monosensitized to HBV (n 5 54) Double sensitized to HBV + YJV (n 5 90)
Total IgE (kU/L) 40.9 (31.5-53.0) [4.20-260] 139 (111-175) [13.8-1374]***
sIgE to HBV (i1) (kUA/L) 2.96 (2.08-4.22) [0.38-53.8] 8.55 (6.49-11.3) [0.73-268]***
sIgE to rApi m 1 (kUA/L) 0.67 (0.41-1.09) [0.01-49.7] 67% 1.28 (0.89-1.86) [0.06-108]* 76%
sIgE to rApi m 2 (kUA/L) 0.08 (0.05-0.14) [0.00-13.0] 28% 0.59 (0.40-0.87) [0.00-113]*** 60%
sIgE to rApi m 3 (kUA/L) 0.15 (0.09-0.24) [0.01-12.6] 28% 0.72 (0.50-1.04) [0.03-77.8]*** 63%
sIgE to nApi m 4 (kUA/L) 0.08 (0.05-0.13) [0.00-24.2] 17% 0.18 (0.13-0.26) [0.00-84.8]*** 27%
sIgE to rApi m 5 (kUA/L) 0.26 (0.16-0.41) [0.01-8.27] 39% 0.64 (0.45-0.89) [0.02-30.2]** 70%
sIgE to Api m 10 (kUA/L) 0.24 (0.14-0.41) [0.00-14.4] 43% 1.08 (0.73-1.59) [0.00-66.6]*** 73%
Monosensitized, ie, HBV-allergic patients sensitized to BV extract (i1) only (n 5 54); double sensitized, ie, HBV-allergic patients sensitized to both HBV extract (i1) and YJV
extract (i3) (n 5 90). Geometric mean (95% CI) [Range]; %; percentage of patients having sIgE >_0.35 kUA/L; *P < .05; **P < .01; ***P < .001 (Mann-Whitney U test).
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TABLE E2. Total IgE, sIgE to YJV extract and to CCD-free YJV allergens Ves v 1 and Ves v 5 in YJV allergic patients monosensitized
to YJV extract or double sensitized to YJV and BV extract
Monosensitized to YJV (n 5 103) Double sensitized to YJV + HBV (n 5 67)
Total IgE (kU/L) 44.8 (36.9-54.3) [3.50-492] 134 (100-180) [5.9-1589]***
sIgE to YJV (i3) (kUA/L) 2.73 (2.14-4.49) [0.42-34.0] 8.28 (6.35-10.8) [0.56-54.7]***
sIgE to rVes v 1 (kUA/L) 0.16 (0.10-0.25) [0.00-42.7] 39% 0.73 (0.41-1.29) [0.00-67.0]*** 66%
sIgE to rVes v 5 (kUA/L) 1.83 (1.35-2.47) [0.01-40.1] 92% 4.06 (2.63-6.27) [0.01-56.1]*** 94%
To address if the phenomenon (higher sIgE in double sensitized as compared to monosensitized patients) is specific for HBV allergy (Table E1) or a more general phenomenon
we analyzed a population of YJV allergic patients (n 5 170). The diagnosis of YJV allergy was based on a positive anaphylactic sting reaction to YJ (as identified by the patient),
a positive skin test and positive sIgE to YJV extract i3 as recently described.15 When comparing monosensitized to double-sensitized patients we observed the same pattern, ie,
higher total IgE and higher specific IgE to YJV or to the YJV allergens rVes v 5 and rVes v 1. Since both allergens are CCD-free and species-specifc (ie, have no corresponding
homologous allergen in HBV) this data confirms our initial interpretation that this observation is independent of CCD or protein cross-reactivity. Monosensitized, ie, YJV-allergic
patients sensitized to YJV extract (i3) only (n 5 103); double sensitized, ie, YJV-allergic patients sensitized to both YJV extract (i3) and BVextract (i1) (n 5 67). Geometric mean
(95 % CI) [Range]; %; percentage of patients having sIgE >_0.35 kUA/L; ***P < .001 (Mann-Whitney U test).
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TABLE E3. Sensitization profiles to 6 HBV allergens in 144 patients with HBV allergy ordered in decreasing frequency
Api m 1 Api m 2 Api m 3 Api m 4 Api m 5 Api m 10 No. Percent Cumulative percent
d d d d d 21 14.58 14.58
d 17 11.81 26.39
d d d d d d 14 9.72 36.11
d d d d 11 7.64 43.75
d d d d 6 4.17 47.92
d 6 4.17 52.08
d d 5 3.47 55.56
d d d 4 2.78 58.33
d d d d d 4 2.78 61.11
d d 4 2.78 63.89
d d d 3 2.08 65.97
d d 3 2.08 68.06
d d 3 2.08 70.14
d 3 2.08 72.22
d d d d 2 1.39 73.61
d d d d 2 1.39 75.00
d d d 2 1.39 76.39
d d d 2 1.39 77.78
d d 2 1.39 79.17
d d d 2 1.39 80.56
d d d 2 1.39 81.94
d 2 1.39 83.33
d d d d 1 0.69 84.03
d d d d d 1 0.69 84.72
d d d 1 0.69 85.42
d d d d 1 0.69 86.11
d d 1 0.69 86.81
d d d d 1 0.69 87.50
d d 1 0.69 88.19
d d d d d 1 0.69 88.89
d d d d 1 0.69 89.58
d d d 1 0.69 90.28
d d d d 1 0.69 90.97
d d d d 1 0.69 91.67
d d 1 0.69 92.36
d d 1 0.69 93.06
d d 1 0.69 93.75
d 1 0.69 94.44
8 5.56 100.00
144 100.00
Dots indicate the presence of sIgE (>_0.35 kUA/L).
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TABLE E4. sIgE profile to recombinant HBV allergens of patients with a convincing history of anaphylactic bee sting reactions that
were negative (<0.35 KU/L) for sIgE to HBV extract (n 5 14)
Patient no.
Clinical sting reaction tIgE
sIgE to HBV
(ImmunoCAP i1)
sIgE to
Api m 1
sIgE to
Api m 3
sIgE to
Api m 4
sIgE to
Api m 10 Skin test
Anaphylaxis grade
(Ring and Messmer) kU/L kUA/L kUA/L kUA/L kUA/L kUA/L HBV SPT HBV i.c.
1 2 28.5 0.21 0.06 0.00 0.00 0.08 1 ND
2 3 <2.0 0.09 0.05 0.02 0.02 0.02 2 1
3 1 34.80 0.06 0.00 0.00 0.00 0.00 1 ND
4 1 74.70 0.08 0.02 0.01 0.02 0.01 2 2
5 3 74.60 0.08 0.03 0.01 0.03 0.02 2 2
6 2 57.50 0.12 0.09 0.06 0.08 0.08 2 2
7 3 29.00 0.31 0.00 0.05 0.00 0.10 2 2
8 2 531.00 0.05 0.00 0.00 0.00 0.00 2 2
9 2 42.10 0.06 0.00 0.00 0.01 0.01 2 2
10 1 32.20 0.10 0.05 0.03 0.05 0.04 1 ND
11 3 12.60 0.05 0.00 0.00 0.00 0.00 2 2
12 1 231.00 0.34 0.19 0.07 0.00 0.03 2 2
13 3 23.90 0.27 0.05 0.02 0.00 0.01 2 1
14 2 41.50 0.25 0.01 0.00 0.02 0.02 2 2
tIgE, Total Ig; i.c., intracutaneous.
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